Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

89Zr-DFOsq-olaratumab

Radiopharmaceutical · Acts on PDGFRA · developed by Telix Pharmaceuticals Pty

Phase 1 Most advanced trial

TLX Developer

1 Registered trials

What is 89Zr-DFOsq-olaratumab?

89Zr-DFOsq-olaratumab is a radiopharmaceutical comprising olaratumab, a monoclonal antibody targeting PDGFRA, labeled with zirconium-89 for imaging. It is being studied in soft tissue sarcoma and PDGFRA-positive solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Radiopharmaceutical
Targets: PDGFRA
Mechanism: Acts on PDGFRA
Therapy area: Oncology
Developer: Telix Pharmaceuticals Pty Ltd (TLX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06537596	Phase 1	Soft Tissue Sarcoma	Recruiting	TLX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

PDGFR Alpha Positive Solid TumoursSoft Tissue Sarcoma

Other drugs acting on PDGFRA

Midostaurin FDA approved Nintedanib FDA approved Regorafenib FDA approved Sunitinib FDA approved

More from Telix Pharmaceuticals Pty

177Lu girentuximab Phase 1/2 177Lu-TLX591 Phase 3 Copper Cu 64-DOTA-TLX592 Early Phase 1 Iodine I 131 IPA Phase 1 Lutetium Lu 177 Rosopatamab Tetraxetan Phase 2 Samarium Sm 153-DOTMP Phase 1 Zirconium Zr 89 Girentuximab Phase 3

Sources

ClinicalTrials.gov NCT06537596

Updated Oct 3, 2026. Something wrong or missing? Report it on the TLX page.

Follow TLX, the company behind 89Zr-DFOsq-olaratumab

See TLX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TLX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z